share_log

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Benzinga Real-time News ·  Aug 16, 2022 07:30

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment